Search

Your search keyword '"S. Ishigo"' showing total 6 results
Start Over Author "S. Ishigo" Topic carbapenems
6 results on '"S. Ishigo"'

1. [Nationwide surveillance of parenteral antibiotics containing meropenem activities against clinically isolated strains in 2002].

Author

Yamaguchi K, Ishii Y, Iwata M, Yoshida H, Satoh T, Watanabe N, Uehara N, Murakami M, Takahashi A, Yasujima M, Kasai T, Itoh K, Shibuya Y, Suwabe A, Obata R, Kanno H, Kubo S, Kaku M, Kanemitsu K, Maesaki S, Hashikita G, Igari J, Oguri T, Aihara M, Kinoshita S, Okada J, Tazawa Y, Taminato T, Negayama K, Nakashima H, Takemura H, Murase M, Miyamoto H, Horii T, Kusano N, Mihara E, Baba H, Ishigo S, Kambe M, Itaha H, Fujita N, Komori T, Ono J, Yoshimura H, Ichiyama S, Maeda S, Hirakata Y, Matsuda J, Yamanaka K, Murata Y, Saikawa T, and Hiramatsu K

Subjects
Bacteria isolation & purification, Bacterial Infections microbiology, Drug Resistance, Bacterial, Humans, Japan, Meropenem, Product Surveillance, Postmarketing, Time Factors, Bacteria drug effects, Carbapenems pharmacology, Thienamycins pharmacology
Abstract

The antibacterial activity of meropenem (MEPM) and other parenteral antibiotics against clinical isolates of 899 strains of Gram-positive bacteria, 1500 strains of Gram-negative bacteria, and 158 strains of anaerobic bacteria obtained from 28 medical institutions during 2002 was measured. The results were as follows; 1. MEPM was more active than other carbapenem antibiotics against Gram-negative bacteria, especially against enterobacteriaceae and Haemophilus influenzae. MIC90 of MEPM against Pseudomonas aeruginosa was the lowest of the drugs tested. MEPM showed low cross-resistant rate against both imipenem-resistant P. aeruginosa and ciprofloxacin-resistant P. aeruginosa. MEPM was active against most of the species tested in Gram-positive and anaerobic bacteria, except for multi-drug resistant strains including methicillin-resistant Staphylococcus aureus (MRSA), methicillin-resistant Staphylococcus epidermidis (MRSE). 2. The proportion of extended-spectrum beta-lactamase (ESBL) strains was 3.1% (4 strains) in Escherichia coli and 1.9% (2 strains) in Klebsiella pneumoniae. Carbapenems including MEPM were active against these ESBL strains. In conclusion, the results from this surveillance study suggest that MEPM retains its potent and broad antibacterial activity and therefore is a clinically useful carbapenem; at present, 7 years after available for commercial use.

Published
2004

2. [Changes in the antibacterial activity of chemotherapeutic agents (especially carbapenems) for 10 species of clinical isolates between 1994 and 1996. Surveillance group of the sensitivities of clinical isolates to antibacterial agents].

Author

Igari J, Watanabe N, Uehara N, Inoue M, Yoshida H, Imafuku Y, Nishino T, Shibano T, Satou S, Kobayashi I, Takahashi A, Yomoda S, Matsuoka K, Oguri T, Ohba Y, Kumasaka K, Tokuda K, Kobayashi Y, Hongo T, Okada J, Sasaki T, Matsumoto N, Hirata Y, Nakasaki N, Ono J, Takata T, Kawaguchi R, Ohtaki Y, Kajimura K, Ishigo S, Hashimoto T, Aoki N, Okamoto E, Murakami E, and Saeki H

Subjects
Bacteria isolation & purification, Drug Resistance, Microbial, Humans, Imipenem pharmacology, Japan, Meropenem, Multicenter Studies as Topic, Thienamycins pharmacology, Time Factors, Bacteria drug effects, Carbapenems pharmacology
Abstract

During October and December of each year of from 1994 to 1996, 3,849 strains of 10 species of bacteria were isolated from clinical materials in 21 institutions nationwide. The minimum inhibitory concentrations (MICs) for these bacteria of four carbapenems (imipenem [IPM], panipenem [PAPM], meropenem [MEPM], and biapenem [BIPM]) and other representative antibacterial agents were measured to investigate annual changes in antibacterial activity. Carbapenems showed potent activity against methicillin-sensitive S. aureus (MSSA), S. pneumoniae, E. faecalis, H. influenzae, E. coli, K. pneumoniae, E. cloacae, S. marcescens, and the B. fragilis group, with the activity being stable. However, these drugs showed weak activity against methicillin-resistant S. aureus (MRSA) and P. aeruginosa. The antibacterial activity (MIC90) against the tested organisms generally remained stable. Particularly, there was annual improvement of the MIC90 values of IPM and BIPM for S. pneumoniae, as well as the values of IPM and PAPM for H. influenzae, and those of IPM, PAPM, and BIPM for S. marcescens. On the other hand, the activity of carbapenems (including IPM) against MRSA was not necessarily strong, but there was annual improvement of MIC90 values.

Published
2000

3. [Survey of the sensitivities of clinical isolates to antibacterial agents (annual report)].

Author

Igari J, Inoue M, Nishino T, Watanabe N, Uehara N, Yoshida H, Imafuku Y, Shibano T, Satou S, Kobayashi I, Takahashi A, Yomoda S, Oguri T, Kumasaka K, Kobayasi Y, Okada J, Hirata Y, Nakasaki N, Kawaguchi R, Ohtaki Y, Ishigo S, Okamoto E, Murakami E, Matsuoka K, and Saeki H

Subjects
Drug Resistance, Microbial, Enterococcus faecalis drug effects, Enterococcus faecalis isolation & purification, Escherichia coli drug effects, Escherichia coli isolation & purification, Humans, Pseudomonas aeruginosa drug effects, Pseudomonas aeruginosa isolation & purification, Serratia marcescens drug effects, Serratia marcescens isolation & purification, Staphylococcus aureus isolation & purification, Streptococcus pneumoniae isolation & purification, Carbapenems pharmacology, Staphylococcus aureus drug effects, Streptococcus pneumoniae drug effects
Abstract

Research groups were formed in 21 institutions nationwide to investigate carbapenem resistance. The activities of various antibacterial agents, principally carbapenems were tested against clinical isolates collected from these institutions. The broth microdilution method was used to determine the minimum inhibitory concentrations (MIC) of 17 antibacterial agents for 1,282 strains of 11 bacterial species isolated at all institutions between October and December 1995. The results were as follows: 1. Carbapenems exhibited strong antibacterial activities against MSSA and Streptococcus pneumoniae. Their activities against Enterococcus faecalis were comparable to that of ABPC. Carbapenems showed low activities against MRSA. 2. OFLX exhibited the greatest antibacterial activity against Haemophilus influenzae, followed by MEPM. The antibacterial activities of the other carbapenems were comparable to those of FMOX and CTM. 3. The carbapenems showed high activities against Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, and Bacteroides fragilis group. Their activities were greater than that exhibited by other beta-lactam antibacterial agents. The carbapenems also exhibited greater antibacterial activities against Serratia marcescens than the other beta-lactam antibacterial agents, but some resistant strains were detected. 4. The antibacterial activities of carbapenems against Pseudomonas aeruginosa were comparable to those of CAZ, AZT, AMK.

Published
1998

4. [Survey of sensitivities of clinical isolates to antibacterial agents (annual report)].

Author

Igari J, Inoue M, Nishino T, Watanabe N, Uehara N, Yoshida H, Imafuku Y, Shibano T, Satou S, Kobayashi I, Takahashi A, Yomoda S, Oguri T, Kumasaka K, Okada J, Hirata Y, Uchida K, Kawaguchi R, Ohtaki Y, Ishigo S, Okamoto E, Murakami E, Matsuoka K, Tokuda K, and Saeki H

Subjects
4-Quinolones, Aminoglycosides, Anti-Bacterial Agents pharmacology, Anti-Infective Agents pharmacology, Cephalosporins pharmacology, Drug Resistance, Microbial, Gram-Negative Bacteria drug effects, Gram-Positive Cocci drug effects, Haemophilus influenzae drug effects, Humans, Imipenem pharmacology, Meropenem, Monobactams pharmacology, Penicillins pharmacology, Pseudomonas aeruginosa drug effects, Serratia marcescens drug effects, Bacteria drug effects, Carbapenems pharmacology, Thienamycins pharmacology
Abstract

Research groups were formed in 20 institutions nationwide to investigate carbapenem resistance of clinical isolates. Activities of various antibacterial agents, principally carbapenems, were tested against clinical isolates collected from these institutions. The broth microdilution method was used to determine the minimum inhibitory concentrations (MICs) of 17 antibacterial agents for 1,326 strains of 11 bacterial species isolated at the institutions between October and December 1994. The results are as follows: 1. Carbapenems exhibited strong antibacterial activities against MSSA and Streptococcus pneumoniae. Their activities against Enterococcus faecalis were comparable to that of ABPC. Carbapenems showed low activities against MRSA. 2. OFLX exhibited the greatest antibacterial activity against Haemophilus influenzae, followed by MEPM. Antibacterial activities of the other carbapenems were comparable to those of FMOX, CTM, and ABPC. 3. The carbapenems showed high activities against Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, and Bacteroides fragilis group. Their activities were greater than those exhibited by other beta-lactam antibacterial agents. The carbapenems also exhibited stronger antibacterial activities against Serratia marcescens than the other beta-lactam antibacterial agents, but some resistant strains were detected. 4. The antibacterial activities of carbapenems against Pseudomonas aeruginosa were comparable to those of CAZ, AZT, AMK.

Published
1997

5. [Changes in the antibacterial activity of chemotherapeutic agents (especially carbapenems) for 10 species of clinical isolates between 1994 and 1996. Surveillance group of the sensitivities of clinical isolates to antibacterial agents]

Author

J, Igari, N, Watanabe, N, Uehara, M, Inoue, H, Yoshida, Y, Imafuku, T, Nishino, T, Shibano, S, Satou, I, Kobayashi, A, Takahashi, S, Yomoda, K, Matsuoka, T, Oguri, Y, Ohba, K, Kumasaka, K, Tokuda, Y, Kobayashi, T, Hongo, J, Okada, T, Sasaki, N, Matsumoto, Y, Hirata, N, Nakasaki, J, Ono, T, Takata, R, Kawaguchi, Y, Ohtaki, K, Kajimura, S, Ishigo, T, Hashimoto, N, Aoki, E, Okamoto, E, Murakami, and H, Saeki

Subjects
Imipenem, Time Factors, Bacteria, Carbapenems, Japan, Humans, Multicenter Studies as Topic, Drug Resistance, Microbial, Thienamycins, Meropenem
Abstract

During October and December of each year of from 1994 to 1996, 3,849 strains of 10 species of bacteria were isolated from clinical materials in 21 institutions nationwide. The minimum inhibitory concentrations (MICs) for these bacteria of four carbapenems (imipenem [IPM], panipenem [PAPM], meropenem [MEPM], and biapenem [BIPM]) and other representative antibacterial agents were measured to investigate annual changes in antibacterial activity. Carbapenems showed potent activity against methicillin-sensitive S. aureus (MSSA), S. pneumoniae, E. faecalis, H. influenzae, E. coli, K. pneumoniae, E. cloacae, S. marcescens, and the B. fragilis group, with the activity being stable. However, these drugs showed weak activity against methicillin-resistant S. aureus (MRSA) and P. aeruginosa. The antibacterial activity (MIC90) against the tested organisms generally remained stable. Particularly, there was annual improvement of the MIC90 values of IPM and BIPM for S. pneumoniae, as well as the values of IPM and PAPM for H. influenzae, and those of IPM, PAPM, and BIPM for S. marcescens. On the other hand, the activity of carbapenems (including IPM) against MRSA was not necessarily strong, but there was annual improvement of MIC90 values.

Published
2000

6. [Survey of sensitivities of clinical isolates to antibacterial agents (annual report)]

Author

J, Igari, M, Inoue, T, Nishino, N, Watanabe, N, Uehara, H, Yoshida, Y, Imafuku, T, Shibano, S, Satou, I, Kobayashi, A, Takahashi, S, Yomoda, T, Oguri, K, Kumasaka, J, Okada, Y, Hirata, K, Uchida, R, Kawaguchi, Y, Ohtaki, S, Ishigo, E, Okamoto, E, Murakami, K, Matsuoka, K, Tokuda, and H, Saeki

Subjects
4-Quinolones, Bacteria, Drug Resistance, Microbial, Meropenem, Penicillins, Haemophilus influenzae, Anti-Bacterial Agents, Cephalosporins, Gram-Positive Cocci, Imipenem, Aminoglycosides, Anti-Infective Agents, Carbapenems, Gram-Negative Bacteria, Pseudomonas aeruginosa, Humans, Thienamycins, Serratia marcescens, Monobactams
Abstract

Research groups were formed in 20 institutions nationwide to investigate carbapenem resistance of clinical isolates. Activities of various antibacterial agents, principally carbapenems, were tested against clinical isolates collected from these institutions. The broth microdilution method was used to determine the minimum inhibitory concentrations (MICs) of 17 antibacterial agents for 1,326 strains of 11 bacterial species isolated at the institutions between October and December 1994. The results are as follows: 1. Carbapenems exhibited strong antibacterial activities against MSSA and Streptococcus pneumoniae. Their activities against Enterococcus faecalis were comparable to that of ABPC. Carbapenems showed low activities against MRSA. 2. OFLX exhibited the greatest antibacterial activity against Haemophilus influenzae, followed by MEPM. Antibacterial activities of the other carbapenems were comparable to those of FMOX, CTM, and ABPC. 3. The carbapenems showed high activities against Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, and Bacteroides fragilis group. Their activities were greater than those exhibited by other beta-lactam antibacterial agents. The carbapenems also exhibited stronger antibacterial activities against Serratia marcescens than the other beta-lactam antibacterial agents, but some resistant strains were detected. 4. The antibacterial activities of carbapenems against Pseudomonas aeruginosa were comparable to those of CAZ, AZT, AMK.

Published
1997

Catalog

Books, media, physical & digital resources
See catalog results